Involvement of central nervous system in adult patients with acute myeloid leukemia: Incidence and impact on outcome
Incidence and impact on outcome of central nervous system (CNS) involvement in adult patients with acute myeloid leukemia (AML) is not clearly defined. Methods. To address this issue, 103 consecutive adult patients with newly diagnosed AML, regardless of neurologic symptoms, were submitted to a routine explorative lumbar puncture. Cerebrospinal fluid (CSF) samples were collected from 65 males and 38 females. All 103 CSF samples were examined by conventional cytology (CC) whereas 95 (92%) also by flow cytometry (FCM). (Source: Seminars in Hematology)
Source: Seminars in Hematology - February 21, 2018 Category: Hematology Authors: Maria Ilaria Del Principe, Francesco Buccisano, Stefano Soddu, Luca Maurillo, Mariagiovanna Cefalo, Alfonso Piciocchi, Maria Irno Consalvo, Giovangiacinto Paterno, Chiara Sarlo, Eleonora De Bellis, Annagiulia Zizzari, Gottardo De Angelis, Daniela Fraboni, Source Type: research
Mechanisms of Complement-Mediated Damage in Hematological Disorders
The complement cascade is an ancient defense system that destroys and eliminates threats to normal homeostasis in the bloodstream and tissues. Although multiple controls keep complement in check to minimize innocent bystander injury to normal cells and tissues, defects in complement regulation due to mutations in, or autoantibodies to, complement control proteins underlie the pathogenesis of several hemolytic diseases including paroxysmal nocturnal hemoglobinuria, and atypical hemolytic uremic syndrome. (Source: Seminars in Hematology)
Source: Seminars in Hematology - February 15, 2018 Category: Hematology Authors: Ronald P. Taylor, Margaret A. Lindorfer Tags: Review Source Type: research
Expanding Complement Therapeutics for the Treatment of Paroxysmal Nocturnal Hemoglobinuria
Paroxysmal nocturnal hemoglobinuria (PNH) is widely regarded as an archetypal complement-mediated disorder that has propelled complement drug discovery in recent decades. Its pathology is driven by chronic complement dysregulation resulting from the lack of the glycosyl phosphatidyl inositol-linked regulators DAF and CD59 on susceptible erythrocytes. This complement imbalance fuels persistent C3 activation on affected erythrocytes, which culminates in chronic complement-mediated intravascular hemolysis. (Source: Seminars in Hematology)
Source: Seminars in Hematology - February 15, 2018 Category: Hematology Authors: Dimitrios C. Mastellos, Edimara S. Reis, Despina Yancopoulou, Antonio M. Risitano, John D. Lambris Tags: Review Source Type: research
Mechanisms of complement-mediated damage in hematological disorders
The complement cascade is an ancient defense system that destroys and eliminates threats to normal homeostasis in the bloodstream and tissues. Although multiple controls keep complement in check to minimize innocent bystander injury to normal cells and tissues, defects in complement regulation due to mutations in, or autoantibodies to, complement control proteins underlie the pathogenesis of several hemolytic diseases including paroxysmal nocturnal hemoglobinuria, and atypical hemolytic uremic syndrome. (Source: Seminars in Hematology)
Source: Seminars in Hematology - February 15, 2018 Category: Hematology Authors: Ronald P. Taylor, Margaret A. Lindorfer Source Type: research
Expanding complement therapeutics for the treatment of paroxysmal nocturnal hemoglobinuria
Paroxysmal nocturnal hemoglobinuria (PNH) is widely regarded as an archetypal complement-mediated disorder that has propelled complement drug discovery in recent decades. Its pathology is driven by chronic complement dysregulation resulting from the lack of the GPI-linked regulators DAF and CD59 on susceptible erythrocytes. This complement imbalance fuels persistent C3 activation on affected erythrocytes, which culminates in chronic complement-mediated intravascular hemolysis. The clinical application of eculizumab, a humanized anti-C5 antibody that blocks terminal pathway activation, has led to drastic improvement of ther...
Source: Seminars in Hematology - February 15, 2018 Category: Hematology Authors: Dimitrios C. Mastellos, Edimara S. Reis, Despina Yancopoulou, Antonio M. Risitano, John D. Lambris Source Type: research
Minimal residual disease in multiple myeloma: use of magnetic resonance imaging
The increasing percentage of patients achieving deep responses in multiple myeloma has led to the need for more sophisticated instruments to measure residual disease as a potential source of relapse. As minimal residual disease assessment is mostly performed on a bone marrow specimen from a certain area of the body, such samples have the limitation that they might not really represent the actual tumor burden, because focal accumulations of malignant cells might be either hit or missed. Magnetic resonance imaging is a highly sensitive technique for the assessment of tumor burden and can be performed as whole-body protocol, ...
Source: Seminars in Hematology - February 12, 2018 Category: Hematology Authors: Jens Hillengass, Maximilian Merz, Stefan Delorme Tags: Review Source Type: research
MRD in multiple myeloma: Utility of MRI
The increasing percentage of patients achieving deep responses in multiple myeloma (MM) has led to the need for more sophisticated instruments to measure residual disease as a potential source of relapse. Since minimal residual disease (MRD) assessment is mostly performed on a bone marrow specimen from a certain area of the body, such samples have the limitation that they might not really represent the actual tumor burden, because focal accumulations of malignant cells might be either hit or missed. (Source: Seminars in Hematology)
Source: Seminars in Hematology - February 12, 2018 Category: Hematology Authors: Jens Hillengass, Maximilian Merz, Stefan Delorme Source Type: research
outside front cover, PMS 8883 metallic AND 4/C
(Source: Seminars in Hematology)
Source: Seminars in Hematology - January 1, 2018 Category: Hematology Source Type: research
Masthead
(Source: Seminars in Hematology)
Source: Seminars in Hematology - January 1, 2018 Category: Hematology Source Type: research
Table of Contents
(Source: Seminars in Hematology)
Source: Seminars in Hematology - January 1, 2018 Category: Hematology Source Type: research
Subcutaneous bortezomib in newly diagnosed patients with multiple myeloma nontransplant eligible: Retrospective evaluation
Bortezomib-melphalan-prednisone combination is one of the standards of care for nontransplant eligible patients with newly diagnosed multiple myeloma. However, bortezomib intravenous (twice weekly for 4 cycles then weekly for 5 cycles) results in ~13% of patients with grade 3-4 peripheral neuropathy. Bortezomib subcutaneous (SQ) and weekly delivery, improves tolerability without impairment of efficacy. The aim of this study was to evaluate the safety and effectiveness of SQ bortezomib-based combinations in nontransplant eligible patients with newly diagnosed myeloma in a real-world setting. (Source: Seminars in Hematology)
Source: Seminars in Hematology - October 13, 2017 Category: Hematology Authors: Felipe de Arriba de la Fuente, Maria Soledad Dur án, Miguel Ángel Álvarez, Isabel López Sanromán, Ana Maria Dios, Rafael Ríos Tamayo, Ricarda García, Marta Sonia González, Elena Prieto, Abelardo Bárez, Fernando Escalante, Aurelia Tejedor, Mónica Tags: Review Source Type: research
Delayed diagnosis of congenital sideroblastic anemia
A 65-year-old woman of Italian and Danish ancestry was referred to our hematology clinic for evaluation of macrocytic anemia and iron overload. Family history was remarkable for anemia in her mother and sister. Her past medical history was significant for anemia since childhood. During her youth she was treated with vitamin B12 supplements without improvement. She was found to have a high transferrin saturation and ferritin and was diagnosed with hemochromatosis by an outside hematologist. However, she tested negative for the C282Y, H63D, and S65C hemochromatosis mutations. (Source: Seminars in Hematology)
Source: Seminars in Hematology - October 13, 2017 Category: Hematology Authors: Ghaith Abu-Zeinah, Mustafa Al-Kawaaz, Julia Geyer, Maria T. DeSancho Source Type: research
Subcutaneous bortezomib in newly diagnosed patients with multiple myeloma nontransplant eligible: Retrospective evaluation
Bortezomib-melphalan-prednisone combination is one of the standards of care for nontransplant eligible patients with newly diagnosed multiple myeloma. However, bortezomib intravenous (twice weekly for 4 cycles then weekly for 5 cycles) results in ~13% of patients with grade 3-4 peripheral neuropathy. Bortezomib subcutaneous (SQ) and weekly delivery, improves tolerability without impairment of efficacy. The aim of this study was to evaluate the safety and effectiveness of SQ bortezomib-based combinations in nontransplant eligible patients with newly diagnosed myeloma in a real-world setting. (Source: Seminars in Hematology)
Source: Seminars in Hematology - October 13, 2017 Category: Hematology Authors: Felipe de Arriba de la Fuente, Maria Soledad Dur án, Miguel Ángel Álvarez, Isabel López Sanromán, Ana Maria Dios, Rafael Ríos Tamayo, Ricarda García, Marta Sonia González, Elena Prieto, Abelardo Bárez, Fernando Escalante, Aurelia Tejedor, Mónica Tags: Review Source Type: research
Subcutaneous bortezomib in newly diagnosed multiple myeloma patients non-transplant eligible: Retrospective evaluation
Bortezomib-melphalan-prednisone combination is one of the standards of care for non-transplant eligible patients with newly diagnosed multiple myeloma. However, bortezomib intravenous (twice weekly/4 cycles then weekly/5 cycles) results in ~13% of patients with grade 3-4 peripheral neuropathy. Bortezomib subcutaneous and weekly delivery, improves tolerability without impairment of efficacy. The aim of this study was to evaluate the safety and effectiveness of subcutaneous bortezomib-based combinations in non-transplant eligible patients with newly diagnosed myeloma in a real-world setting. (Source: Seminars in Hematology)
Source: Seminars in Hematology - October 13, 2017 Category: Hematology Authors: Felipe de Arriba de la Fuente, Maria Soledad Dur án, Miguel Ángel Álvarez, Isabel López Sanromán, Ana Maria Dios, Rafael Ríos Tamayo, Ricarda García, Marta Sonia González, Elena Prieto, Abelardo Bárez, Fernando Escalante, Aurelia Tejedor, Mónica Source Type: research
